Loading...
Market
Story
Pfizer's RSV Vaccine Abrysvo Shows Positive Results in Study
Aug 12, 2024, 10:48 AM
Pfizer announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has shown positive results in a late-stage study involving immunocompromised adults. The study demonstrated that Abrysvo generated a strong immune response across four groups of adults. This development marks a significant step for Pfizer as it seeks to expand its vaccine offerings and address the needs of vulnerable populations.
View original story
Similar markets
Canada • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
USA • 25%
EU • 25%
Canada • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Johnson & Johnson • 25%
AstraZeneca • 25%
Sanofi • 25%
Other • 25%